Clinical trials: AMI Patients
Myocardial Infarction, Acute ST-Segment Elevation
Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)
The primary objective of the study is to determine whether enoxaparin compared to unfractionated heparin will reduce the composite endpoint of all-cause mortality and non-fatal myocardial re-infarction within 30 days after…
- Trial name
- NCT00077792
- Testing
- Enoxaparin sodium (XRP4563)
- Where
- 48 sites in United States, Argentina and 46 more
- Volunteers
- 20,506 people
- Sponsor
- Sanofi
Acute Coronary Syndromes
A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
The purpose of this study is to determine if Apixaban is safer than a Vitamin K Antagonist given for 6 months in terms of bleeding in patients with an irregular heart beat (atrial fibrillation) and a recent heart attack or a…
- Trial name
- NCT02415400
- Testing
- Apixaban, vitamin K antagonist, Acetylsalicylic acid
- Where
- 626 sites in United States, Argentina and 35 more
- Volunteers
- 4,614 people
- Sponsor
- Bristol-Myers Squibb
Myocardial Infarction, Cardiogenic Shock
Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction
Cardiogenic shock is the most severe manifestation of acute heart failure and remains the leading cause of death in patients hospitalised with acute myocardial infarction.
- Trial name
- NCT06955936
- Testing
- Efferon CT
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- Efferon JSC
Post Myocardial Infarction
Open-label Extension Study for CLCZ696G2301 (PARADISE-MI)
The purpose of this study is to collect long-term safety and tolerability data of LCZ696 and to provide open-label LCZ696 to eligible participants who completed CLCZ696G2301 study (PARADISE-MI) if LCZ696 is shown to have a…
- Trial name
- NCT04637555
- Testing
- sacubitril/valsartan
- Sponsor
- Novartis Pharmaceuticals
Myocardial Infarction (MI)
Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction
Thi is is a multi-center, randomized, single-blind, parallel group clinical trial to evaluate the efficacy and safety of the intravenious thrombolysis with Revelise® (GENERIUM, Russia) in comparosin with the Actilyse® (Boehringer…
- Trial name
- NCT07146360
- Testing
- Revelise (GENERIUM, Russia), Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)
- Where
- 22 sites in Russia
- Volunteers
- 180 people
- Sponsor
- AO GENERIUM
Anterior Myocardial Infarction
A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction
The research study is being done to see if SGC001 can be used to treat people scheduled to undergo percutaneous coronary intervention for Anterior ST-segment Elevation Myocardial Infarction.
- Trial name
- NCT07091929
- Testing
- SGC001
- Where
- 4 sites in China
- Volunteers
- 38 people
- Sponsor
- Beijing Sungen Biomedical Technology Co., Ltd
Diabetes Mellitus, Type 2
A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.
- Trial name
- THEMIS (NCT01991795)
- Testing
- Ticagrelor 60 mg
- Where
- 1,237 sites in United States, Argentina and 41 more
- Volunteers
- 19,271 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180)
A-Phase: Evaluating patients with chest pain who are receiving approved drugs, to estimate the effectiveness of one type of blood thinner as compared to another type of blood thinner.
- Trial name
- NCT00251576
- Testing
- A-Phase: tirofiban; Z-Phase simvastatin, Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years, Comparator: A-Phase: low molecular weight heparin, unfractionated heparin
- Volunteers
- 4,497 people
- Sponsor
- Organon and Co
Cardiogenic Shock, STEMI
Incorporating Supersaturated Oxygen in Shock
A multi-center, prospective randomized (1:1) pilot and feasibility study to evaluate the safety and feasibility of supersaturated oxygen (SSO2) therapy delivered for 60 minutes selectively into the culprit coronary artery of…
- Trial name
- ISO-SHOCK (NCT04876040)
- Testing
- SSO2 Downstream System, PCI + Impella
- Where
- 7 sites in United States
- Sponsor
- TherOx
Anterior Wall Acute Myocardial Infarction
Evaluation of Intracoronary Hyperoxemic Oxygen Therapy in Anterior Acute Myocardial Infarction Patients (IC-HOT)
The primary objective of the study is to collect confirmatory data supporting the safety and effectiveness of SSO2 Therapy in treatment of anterior acute myocardial infarction (AMI) patients who have undergone successful…
- Trial name
- IC-HOT (NCT02603835)
- Testing
- SSO2 Therapy
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- TherOx
Myocardial Infarction (MI)
Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice
This is an observational study based on secondary data extracted from multiple register-based data sources in the US and Europe (Sweden, United Kingdom, Italy, Germany).
- Trial name
- ALETHEIA (NCT04568083)
- Where
- 6 sites in United States, Germany and 3 more
- Volunteers
- 7,035 people
- Sponsor
- AstraZeneca
Peripheral Artery Disease
A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease
The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.
- Trial name
- EUCLID (NCT01732822)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 776 sites in United States, Argentina and 26 more
- Volunteers
- 13,885 people
- Sponsor
- AstraZeneca
Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events
Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events
To estimate ischemic event rates in individuals with established atherosclerotic cardiovascular disease (ASCVD) and no prior acute ischemic events, comparing alirocumab with no Proprotein Convertase Subtilisin/Kexin type 9…
- Trial name
- OPTIMUS-EPIC (NCT07734753)
- Testing
- Alirocumab, Comparator: No PCSK9i Therapy (monoclonal antibodies or small interfering RNA agents)
- Where
- Netherlands
- Volunteers
- 4,006 people
- Sponsor
- Sanofi
Myocardial Infarction
MCG Post Myocardial Infarction Study
The study is being performed to evaluate a new portable medical device, the Creavo Vitalscan Magnetocardiograph (Vitalscan) on patients who have had a confirmed myocardial infarction (heart attack) within the previous 12 weeks.
- Trial name
- NCT03358368
- Testing
- Vitalscan
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Creavo Medical Technologies Ltd
Acute Myocardial Infarction
Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Myocardial Infarction
This study is a first-in-human assessment of safety of using UCMSC in patients with AMI via a combination of IC and IV stem cell administration.
- Trial name
- NCT04056819
- Testing
- Allogeneic umbilical cord mesenchymal stem cells
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- Ever Supreme Bio Technology Co., Ltd.
AMI
Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction
Primary objective: To demonstrate that in hyperglycemic subjects with anterior STEMI (ST Elevation Myocardial Infarction) undergoing Percutaneous Coronary Intervention (PCI), tight glycemic control using insulin glulisine and…
- Trial name
- INTENSIVE (NCT00670228)
- Testing
- Insulin Glargine (LANTUS), Insulin Glulisine (Apidra), Standard Therapy
- Where
- 5 sites in United States, Argentina and 3 more
- Volunteers
- 34 people
- Sponsor
- Sanofi
Coronary Artery Diseases
BIOFLOW-III VIP Russia Registry Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). Along with it, an explanatory (hypothesis-finding) problem will be investigated, whether the patient's body…
- Trial name
- NCT02247492
- Where
- 7 sites in Russia
- Volunteers
- 200 people
- Sponsor
- Biotronik Russia
Diabetes Mellitus, Type 2, Acute Coronary Syndrome
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.
- Trial name
- EXAMINE (NCT00968708)
- Testing
- Alogliptin
- Where
- 908 sites in United States, Argentina and 48 more
- Volunteers
- 5,380 people
- Sponsor
- Takeda
STEMI
The First-In-Man Use of Coronary Sinus Balloon Pump in STEMI Patients Treated by Primary PCI
This is a prospective, multicenter clinical investigation aiming to evaluate the safety and efficacy of the coronary sinus balloon pump in its first application in patients with acute ST-segment elevation myocardial infarction…
- Trial name
- REVIVE-FIM (NCT07082153)
- Testing
- the coronary sinus balloon pump
- Volunteers
- 10 people
- Sponsor
- Shanghai MicroPort Rhythm MedTech Co., Ltd.
Acute Coronary Syndrome
Long-term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients in Russia
EPICOR-RUS is a multi-centre, observational, prospective, longitudinal cohort study which will include patients, in a real-life setting, who are hospitalized for acute coronary syndrome (ACS) within 24 hours of symptom onset and…
- Trial name
- EPICOR-RUS (NCT01373957)
- Where
- 19 sites in Russia
- Volunteers
- 600 people
- Sponsor
- AstraZeneca